➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Dow
Merck

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 9,918,939

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,918,939
Title:Formulation of Syk inhibitors
Abstract: Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition. ##STR00001##
Inventor(s): Casteel; Melissa Jean (Foster City, CA), Li; Bei (Foster City, CA), Pakdaman; Rowchanak (Foster City, CA), Sperger; Diana (Foster City, CA), Stefanidis; Dimitrios (Mountain View, CA)
Assignee: Gilead Connecticut, Inc. (Foster City, CA)
Application Number:14/906,248
Patent Claims:see list of patent claims

Details for Patent 9,918,939

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Gilead Connecticut, Inc. (Foster City, CA) 2033-07-30 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Gilead Connecticut, Inc. (Foster City, CA) 2033-07-30 RX search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Gilead Connecticut, Inc. (Foster City, CA) 2033-07-30 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Gilead Connecticut, Inc. (Foster City, CA) 2033-07-30 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Gilead Connecticut, Inc. (Foster City, CA) 2033-07-30 RX Orphan search
Genentech GAZYVA obinutuzumab INJECTABLE;INJECTION 125486 001 2013-11-01   Start Trial Gilead Connecticut, Inc. (Foster City, CA) 2033-07-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Boehringer Ingelheim
Merck
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.